Schedule 13G/A: Commodore Capital Discloses No SLDB Holdings

Rhea-AI Filing Summary

Solid Biosciences Inc. Schedule 13G/A filing by Commodore Capital entities

Commodore Capital LP and Commodore Capital Master LP filed an amendment to Schedule 13G reporting zero shares beneficially owned of Solid Biosciences Inc. (CUSIP 83422E204), representing 0.0% of the class. The filing lists the issuers' principal office at 500 Rutherford Avenue, Charlestown, Massachusetts, and gives filing addresses for the two filers in New York and the Cayman Islands. Both filers state no sole or shared voting or dispositive power over any shares and certify the securities were not acquired to influence control of the issuer. The filing is signed by Michael Kramarz for both entities and references a Joint Filing Agreement as an exhibit.

Positive

• Full disclosure compliance: The amendment is signed and includes a Joint Filing Agreement exhibit.
• Clear statement of non-ownership: Both filers report 0.00 shares and 0.0% of the class, removing ambiguity about current holdings.

Negative

• None.

Insights

Securities Analyst

TL;DR: The amendment reports no beneficial ownership, indicating the filers hold 0.0% of SLDB and assert no control intent.

The Schedule 13G/A discloses that Commodore Capital LP and Commodore Capital Master LP each report zero shares beneficially owned and 0.0% of the class. All columns for sole and shared voting and dispositive power are reported as 0.00. The filing includes requisite issuer and filer addresses and a certification that the securities were not acquired to influence control. For investors, this filing is a routine ownership disclosure with no direct impact on capitalization or control dynamics because no holdings are reported.

Corporate Governance Expert

TL;DR: Formal compliance filing filed and signed; no reported ownership or group activity.

The document contains a signed certification and an exhibit reference to a Joint Filing Agreement, meeting formal disclosure requirements for Schedule 13G/A amendments. The filers classify themselves as applicable types (IA, PN and PN) on the cover pages and explicitly state not applicable for group identification, ownership over 5%, and related items. The submission documents that neither filer holds voting or dispositive power over Solid Biosciences common stock as of the reported event date.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Solid Biosciences Inc.

(Name of Issuer)

Common Stock $0.001 par value per share

(Title of Class of Securities)

83422E204

(CUSIP Number)

06/30/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 83422E204

1

Names of Reporting Persons

Commodore Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

IA, PN

SCHEDULE 13G

CUSIP No. 83422E204

1

Names of Reporting Persons

Commodore Capital Master LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

0.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

0.0 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Solid Biosciences Inc.
(b)	Address of issuer's principal executive offices: 500 Rutherford Avenue, Charlestown, MASSACHUSETTS, 02129.
Item 2.
(a)	Name of person filing: Commodore Capital LP Commodore Capital Master LP Each a "Filer."
(b)	Address or principal business office or, if none, residence: The address for Commodore Capital LP is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is, c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
(c)	Citizenship: See Item 4 of the cover page for each Filer.
(d)	Title of class of securities: Common Stock $0.001 par value per share
(e)	CUSIP No.: 83422E204
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of the cover page for each Filer.
(b)	Percent of class: See Item 11 of the cover page for each Filer.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of the cover page for each Filer.
	(ii) Shared power to vote or to direct the vote: See Item 6 of the cover page for each Filer.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the cover page for each Filer.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of the cover page for each Filer.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commodore Capital LP

Signature:	Michael Kramarz
Name/Title:	Managing Partner
Date:	08/14/2025

Commodore Capital Master LP

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	08/14/2025

Exhibit Information

Exhibit 1: Joint Filing Agreement

FAQ

What did Commodore Capital report on the Schedule 13G/A for SLDB?

The filers reported zero shares beneficially owned of Solid Biosciences Inc., representing 0.0% of the class.

Who signed the Schedule 13G/A amendment for Solid Biosciences (SLDB)?

The filing is signed by Michael Kramarz as Managing Partner for Commodore Capital LP and as Authorized Signatory for Commodore Capital Master LP on 08/14/2025.

Does the filing indicate the filers have voting or dispositive power over SLDB shares?

No. The filing reports 0.00 for sole and shared voting power and 0.00 for sole and shared dispositive power for each filer.

What addresses are listed for the issuer and filers in the Schedule 13G/A?

Issuer principal office: 500 Rutherford Avenue, Charlestown, Massachusetts 02129. Commodore Capital LP address: 444 Madison Avenue, Floor 35, New York, NY 10022. Commodore Capital Master LP address: c/o Maples Corporate Services Limited, Ugland House, Grand Cayman.

Does the filing state the filers intend to influence control of Solid Biosciences?

No. The certification states the securities were not acquired and are not held for the purpose of changing or influencing control of the issuer.